THC and CBD Suppressed a Key Inflammatory Immune Response Linked to Autoimmune Diseases
Both THC and CBD suppressed the Th17 inflammatory immune response associated with autoimmune diseases like multiple sclerosis, reducing the pathogenic cytokine IL-17 while boosting the anti-inflammatory cytokine IL-10.
Quick Facts
What This Study Found
Researchers studied immune cells that cause experimental autoimmune encephalitis (a model of multiple sclerosis) in mice. When these pathogenic T cells were reactivated, they produced large amounts of IL-17, a cytokine that drives autoimmune inflammation.
Both THC and CBD dose-dependently suppressed IL-17 production and secretion at concentrations of 0.1-5 micromolar. They also reduced IL-6, a key factor in Th17 cell development. CBD additionally increased IL-10, an anti-inflammatory cytokine. Neither cannabinoid affected TNF-alpha or IFN-gamma levels, showing specificity. The effects did not involve CB1, CB2, PPAR-gamma, 5-HT1A, or TRPV1 receptors, indicating a novel mechanism.
Key Numbers
THC and CBD: dose-dependent suppression at 0.1-5 micromolar. Suppressed: IL-17, IL-6. No effect on: TNF-alpha, IFN-gamma. CBD additionally increased IL-10. Receptor-independent: not through CB1, CB2, PPAR-gamma, 5-HT1A, or TRPV1.
How They Did This
In vitro study using MOG35-55-specific encephalitogenic T cells reactivated with spleen-derived antigen presenting cells. THC and CBD tested at 0.1-5 micromolar. Cytokine measurements: IL-17, IL-6, IL-10, TNF-alpha, IFN-gamma. Receptor involvement assessed with selective antagonists.
Why This Research Matters
Th17 cells are major drivers of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and psoriasis. A treatment that specifically suppresses the Th17 response while boosting anti-inflammatory IL-10 would be highly valuable, and cannabinoids appear to do exactly this.
The Bigger Picture
This study reveals that cannabinoids have a highly specific immunomodulatory profile: they suppress the autoimmune Th17 pathway while leaving other immune responses intact and boosting anti-inflammatory responses. This specificity is unusual and therapeutically attractive.
What This Study Doesn't Tell Us
In vitro study with immune cells in a dish, not in living organisms. The concentrations used may not be achievable in the human body. The receptor-independent mechanism was identified by exclusion (blocking known receptors), but the actual target was not identified. Results from autoimmune encephalitis T cells may not generalize to all autoimmune conditions.
Questions This Raises
- ?Through what molecular target do cannabinoids suppress Th17 responses?
- ?Would these effects translate to clinical improvement in MS patients?
- ?Could cannabinoids complement existing immunomodulatory treatments?
- ?Is the CBD-specific IL-10 increase therapeutically meaningful?
Trust & Context
- Key Stat:
- Cannabinoids suppressed pathogenic IL-17 while boosting anti-inflammatory IL-10
- Evidence Grade:
- Well-controlled in vitro study with dose-response data; moderate preclinical evidence for a specific immunomodulatory effect.
- Study Age:
- Published in 2013. The Th17-suppressing properties of cannabinoids continue to be explored for autoimmune applications.
- Original Title:
- Cannabinoids decrease the th17 inflammatory autoimmune phenotype.
- Published In:
- Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 8(5), 1265-76 (2013)
- Authors:
- Kozela, Ewa(2), Juknat, Ana(2), Kaushansky, Nathali(2), Rimmerman, Neta, Ben-Nun, Avraham, Vogel, Zvi
- Database ID:
- RTHC-00693
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could cannabis help treat autoimmune diseases?
This laboratory study shows that both THC and CBD can suppress the specific type of immune response (Th17) that drives autoimmune diseases like multiple sclerosis. While this is promising, it was conducted with cells in a dish, not in patients. The concentrations needed and whether these effects occur in the human body remain to be determined.
Is CBD or THC better for inflammation?
Both suppressed the Th17 inflammatory response similarly. However, CBD had an additional benefit: it increased IL-10, an anti-inflammatory cytokine. This dual action (suppressing pathogenic inflammation while boosting anti-inflammatory responses) may make CBD particularly attractive for autoimmune conditions, though clinical evidence is still needed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00693APA
Kozela, Ewa; Juknat, Ana; Kaushansky, Nathali; Rimmerman, Neta; Ben-Nun, Avraham; Vogel, Zvi. (2013). Cannabinoids decrease the th17 inflammatory autoimmune phenotype.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 8(5), 1265-76. https://doi.org/10.1007/s11481-013-9493-1
MLA
Kozela, Ewa, et al. "Cannabinoids decrease the th17 inflammatory autoimmune phenotype.." Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2013. https://doi.org/10.1007/s11481-013-9493-1
RethinkTHC
RethinkTHC Research Database. "Cannabinoids decrease the th17 inflammatory autoimmune pheno..." RTHC-00693. Retrieved from https://rethinkthc.com/research/kozela-2013-cannabinoids-decrease-the-th17
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.